Iron polymaltose pharma grade API is distributed as a dark brown amorphous powder or granular solid in which polynuclear ferric hydroxide cores are stabilised by partially hydrolysed polymaltose chains. The product is supplied in two service grades: an oral grade for tablet, capsule, and granule processing, and a parenteral grade for injectable solutions. Model designations are manufacturer-specific, but they routinely distinguish oral-grade material with controlled particle size for direct compression or wet granulation from injectable-grade material with reduced bacterial endotoxin burden and subvisible particulate control. Elemental iron content is the principal specification parameter and is determined by complexometric titration; commercial lots are standardised to an elemental iron content of 28–32% w/w, with the exact value reported on the certificate of analysis. Identification is confirmed by infrared absorption spectrophotometry and by the characteristic iron-specific colour reaction. The API is used in oral solids and aqueous injection vehicles because it remains non-ionic at gastric pH and does not release free ferrous ions in the stomach.

The manufacturing route for iron polymaltose starts with controlled alkaline precipitation of ferric iron in the presence of partially hydrolysed starch, followed by purification, concentration, and spray drying or freeze drying. The exact molar ratio of ferric iron to carbohydrate, the degree of starch hydrolysis, and the drying profile determine molecular weight distribution and free-iron content. These parameters are disclosed in the active substance master file and are not interchangeable between suppliers. Consequently, formulators should not substitute oral-grade material from one source with another without repeating blend uniformity and dissolution studies, because the surface chemistry of the polymaltose shell affects tableting performance and dissolution kinetics.

Release specifications include iron titre, pH of a 10% w/v aqueous dispersion, loss on drying, residue on ignition, elemental impurities per ICH Q3D (R1), and microbial quality. The pH is measured potentiometrically according to Ph. Eur. 2.2.3; deviations outside the registered range are taken as evidence of colloidal destabilisation or contamination with free alkali. Loss on drying is performed by Ph. Eur. 2.2.32; excessive residual water affects powder flow and microbial stability. Elemental impurities are controlled by inductively coupled plasma mass spectrometry as described in ICH Q3D (R1); the risk assessment includes nickel, chromium, and lead residues from the starting ferric chloride and starch hydrolysates. The absence of free ferrous ions is established as a limit test, because compendial practice recognises that trace ionic iron can be present without altering the non-ionic delivery profile.

Why Does Iron Polymaltose Resist Free-Iron Dissociation at Gastric pH?

Ferrous sulfate heptahydrate releases Fe²⁺ rapidly in the stomach, producing high intraluminal concentrations that drive Fenton-type hydroxyl radical generation and dose-limiting gastrointestinal irritation. Iron polymaltose complex is a carbohydrate-stabilised polynuclear ferric oxyhydroxide. The polysaccharide shell maintains the iron centre in a non-ionic, kinetically inert state at pH values above 3.0. This difference is exploited in oral formulations where the objective is to minimise intraluminal free-iron concentration. Comparative dissolution testing of finished tablets is performed under compendial conditions such as USP 711 or Ph. Eur. 2.9.3; the free-iron release profile of iron polymaltose is markedly lower than that of ionizable ferrous salts under simulated gastric fluid. Published comparative data are product-specific and are detailed in the finished-product dossier rather than in the API monograph. The clinical formulation boundary is that iron polymaltose should not be blended with strong reducing agents such as ascorbic acid or cysteine before granulation, because these agents can destabilise the complex and increase free-iron release beyond the registered limit.

For tablet and capsule manufacture, the oral grade is typically pre-blended with microcrystalline cellulose, pregelatinised starch, or lactose monohydrate. Direct compression is feasible when the particle size distribution supports uniform die filling; laser diffraction analysis is performed according to ISO 13320:2020. Segregation is most often observed on rotary tablet presses when the API and filler particle size distributions overlap poorly; the corrective action is wet granulation or re-milling of the API. Cleaning validation after processing must account for the dark brown colour and the high iron content of the residue; rinse samples are selected for iron analysis to demonstrate that carryover into the next product is below the assigned cleaning limit. Equipment contact surfaces should be accessible and non-reactive because dried iron polymaltose is difficult to remove from scratched stainless steel. The processing boundary for wet granulation is that high-shear mixing with acidic excipients is restricted; prolonged contact with citric acid, malic acid, or tartaric acid can lower local pH and promote surface iron release.

Granule drying is conducted in fluid-bed dryers or tray dryers depending on batch size. Inlet air temperature should remain within the range recommended by the API manufacturer; typical wet granulation runs use inlet air temperatures below 60°C to prevent darkening and generation of free moisture. Product temperature is monitored continuously, and drying is terminated when loss on drying falls below the registered limit. The API is hygroscopic; when ambient relative humidity exceeds 60%, the powder should be pre-dried before blending and kept in closed containers under dry nitrogen or in air-conditioned suites below 40% RH. These limits are operational boundaries, not finished-product stability endpoints; they are derived from production-scale batch records and are stated in the technical data package.

Wet granulation endpoint is best controlled by power consumption or torque rheometry rather than visual inspection alone. The granulation curve for iron polymaltose formulations shows a narrow plateau; over-granulation generates dense granules with reduced compressibility and slower tablet disintegration. Under-granulation produces friable granules and segregation in the tablet press. Batch record review from production-scale high-shear mixers shows that the addition rate of the binder solution is the primary variable controlling granule size distribution. The free-iron limit test is performed by visible spectrophotometry after reaction with a chelating chromogen such as thiocyanate or ferrozine. The test is configured as a limit test because the specification objective is to ensure that free Fe²⁺/Fe³⁺ remains below the threshold at which oxidative damage or metallic taste occurs. Sample preparation is critical; the complex should be dissolved without acid digestion, because acid digestion itself liberates bound iron and invalidates the free-iron result.

Injectable-Grade Iron Polymaltose: Endotoxin, Molecular Weight, and Stability Boundaries

Parenteral-grade iron polymaltose is differentiated from oral grade by bacterial endotoxin load, subvisible particulate burden, sterility, and free-iron content. Bacterial endotoxins are tested by kinetic chromogenic LAL according to Ph. Eur. 2.6.14; the acceptance criterion is expressed in IU/mL or IU/mg and is product-specific, with injectable materials controlled to a tighter limit than oral grades. Sterility is verified by Ph. Eur. 2.6.1 after terminal sterilisation or aseptic filling. Subvisible particulate matter is assessed by light obscuration particle count test according to Ph. Eur. 2.9.19; compliance with the monograph for parenteral preparations is required. The free-iron limit is critical because free Fe³⁺ in parenteral solutions can cause injection-site reactions and oxidative stress. Compendial practice applies a limit test rather than a quantitative assay for free iron; the exact acceptance limit is stated in the finished-product specification.

Molecular weight distribution is a further injectable-grade control. The hydrodynamic diameter is measured by dynamic light scattering according to ISO 22412:2017. Broad or shifting molecular weight distributions indicate aggregation or degradation of the polymaltose shell. Injectable-grade material is not interchangeable with iron sucrose or ferric carboxymaltose; these products differ in carbohydrate chemistry, molecular mass, and plasma kinetics. Iron sucrose is a smaller non-ionic complex intended for intravenous use; ferric carboxymaltose is a high-molecular-weight dextran-free complex with a different maximum single-dose profile. Published molecular weight data across manufacturers are limited; therefore, interchangeability should not be assumed without batch-specific data and clinical posology.

Injectable-grade aqueous solutions exhibit a brown colloidal appearance; viscosity is monitored as a stability-indicating parameter because depolymerisation of the polymaltose shell can alter viscosity and hydrodynamic diameter. Rotational viscometry is performed with cone-plate geometry at controlled temperature; acceptance limits are product-specific. Significant reduction in viscosity may indicate hydrolysis of the carbohydrate shell, while an increase may indicate aggregation. The complex is compatible with non-reducing sugars and polyols; reducing sugars such as dextrose and maltose may participate in Maillard reactions during terminal sterilisation and are generally avoided in injectable formulations. Oral liquid formulations with sorbitol or maltitol are common. The use of preservatives such as methylparaben and propylparaben is acceptable when supported by preservative efficacy testing per Ph. Eur. 5.1.3.

When Terminal Sterilisation Is Applied to Polymaltose Injection Solutions

Terminal sterilisation by saturated steam at 121°C for 15 min may be applied only after confirming that the formulation remains free of visible precipitation and that the free-iron limit is unchanged. Heat exposure can shift the colloidal equilibrium and increase the proportion of low-molecular-weight iron species; this is a critical process boundary for injectable-grade material. Process validation is required for each product-specific formulation because the presence of tonicity agents, pH buffers, and antioxidants modifies thermal stability. Filtration of the bulk solution before filling is performed with filters that have been qualified for compatibility; the iron polymaltose complex behaves as a colloidal dispersion rather than a true solution, and the filter membrane must not remove the active complex. The filling line should be equipped with in-line particle counting to detect aggregation during the hold period. The maximum hold time between compounding and sterilisation is established in the marketing authorisation; this is a parameter that cannot be extended without stability data.

The API is hygroscopic and should be stored in tightly closed containers; once opened, the working quantity should be divided into single-use aliquots under dry conditions. Bulk containers should be resealed immediately after sampling. Sampling itself is performed in a downflow booth with environmental monitoring below 40% RH; processing of the oral grade in an open granulation suite at higher humidity leads to moisture uptake and loss-on-drying failure at the end of drying. These operational limits are derived from manufacturing-scale experience and are not mandatory compendial controls unless stated in the product authorisation.

Compared with ferrous sulfate heptahydrate, ferrous fumarate, and ferrous bisglycinate, iron polymaltose is non-ionic and does not dissociate into free ferrous ions under gastric conditions. Ferrous sulfate contains approximately 20% elemental iron and is the reference oral iron salt in many monographs; its oxidative incompatibility with ascorbic acid in direct compression is a known tablet quality issue. Ferrous fumarate has lower solubility and requires acid co-administration for reproducible dissolution. Ferrous bisglycinate is an amino acid chelate, not a polysaccharide complex; its absorption pathways and pH sensitivity differ. The clinical processing advantage of iron polymaltose is the absence of metallic taste and reduced staining of equipment, but that advantage must be balanced against a higher raw material cost per kilogram and the need for controlled drying. The API is not appropriate for iron formulations that rely on rapid Fe²⁺ release for same-day bioavailability; its absorption is slower and is more dependent on active mucosal transport.

Compendial Specification Matrix and Analytical Hurdles

Specification testing for iron polymaltose is split between oral and injectable service grades. The table lists the methods that are most frequently encountered in a technical dossier, not the numerical acceptance limits, because limits are product-specific and registered with national authorities.

In addition to the compendial methods, the technical dossier includes a risk assessment for nitrosamines and residual solvents. Residual solvents are controlled by Ph. Eur. 2.4.24 or equivalent. Nitrosamine risk is evaluated according to EMA/FDA guidance, but the typical manufacturing route for iron polymaltose does not use secondary amines or nitrite sources; documentation should nevertheless include a risk statement. The product is not considered a nitrosamine-sensitive API, but process vulnerability remains if recycled equipment is not cleaned of residual amines.

Stability storage is conducted in ICH-compliant chambers at 25°C/60% RH and 40°C/75% RH. The API is protected from light and moisture in double polyethylene bags inside HDPE drums. Under these conditions, the finished oral dosage form is typically assigned a shelf life based on the stability protocol in the market application. The parenteral solution is stored in Type I glass vials with chlorobutyl rubber stoppers; compatibility between the stopper material and the complex is confirmed by extraction studies. Terminal sterilisation and storage can induce slight pH drift, which is monitored as a stability-indicating parameter.

Operational incompatibilities include strong oxidising agents, strong acids, and reducing agents. The API should not be dry-blended with ascorbic acid, cysteine, glutathione, or other reductants because these substances can liberate iron and alter the colour of the granulate. Contact with aluminium or copper equipment is avoided because ferric iron can participate in galvanic corrosion; pharmaceutical-grade stainless steel 316L is preferred. The material is not intended for patients with iron overload states such as hereditary hemochromatosis or haemosiderosis; parenteral administration carries a risk of hypersensitivity reactions and requires resuscitation equipment. Oral iron polymaltose should not be co-administered with levothyroxine or tetracycline without separation of dosing intervals, because iron complexes can reduce the bioavailability of these drugs.